Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Clinician Scientist - Phase 1

University of Toronto

$172,500.00

Making unbiased estimates of treatment effect using observational data in uncommon disease. The scleroderma-pulmonary hypertension model.

FY 2010-11

Summary
Studies of uncommon diseases are challenged by small numbers of patients available for recruitment, and studies are often too small to detect important treatment effects. The Bayesian paradigm allows us to draw inferences with the data at hand, and has the ability to incorporate previous knowledge into estimates of treatment effects. This paradigm is useful in the study of uncommon diseases. An example of an uncommon disease is systemic sclerosis (SSc). SSc is a disease that can affect the skin, joints and lungs. There is no cure. The leading cause of death for Canadians with SSc is high pressure in the lungs called pulmonary arterial hypertension (PAH). Experts suggest use of a blood thinner called warfarin for patients with PAH. A major side effect of warfarin is that it can cause severe bleeding. Whether this drug improves survival is not known. Using a novel research approach, this series of studies will evaluate if warfarin improves survival in SSc-PAH. We will use innovative techniques to study if warfarin improves survival by comparing the survival of SSc-PAH patients who did and did not take warfarin. This research will be the first to study if warfarin improves survival in this deadly disease, and will develop innovative research methods for all researchers who study uncommon diseases.
Program
CIHR Clinician Scientist - Phase 1
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
213305
Name
Johnson Sindhu R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Clinical
Prcname2
Clinician Scientist
Projecttitle
Making unbiased estimates of treatment effect using observational data in uncommon disease. The scleroderma-pulmonary hypertension model.
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$172,500
Cihrequipment2
$0
Programname2
CIHR Clinician Scientist - Phase 1
Keyworddelim
Bayesian; Confounding; Observational; Propensity Score; Pulmonary Hypertension; Scleroderma; Survival; Systemic Sclerosis; Warfarin
Abstract
Studies of uncommon diseases are challenged by small numbers of patients available for recruitment, and studies are often too small to detect important treatment effects. The Bayesian paradigm allows us to draw inferences with the data at hand, and has the ability to incorporate previous knowledge into estimates of treatment effects. This paradigm is useful in the study of uncommon diseases. An example of an uncommon disease is systemic sclerosis (SSc). SSc is a disease that can affect the skin, joints and lungs. There is no cure. The leading cause of death for Canadians with SSc is high pressure in the lungs called pulmonary arterial hypertension (PAH). Experts suggest use of a blood thinner called warfarin for patients with PAH. A major side effect of warfarin is that it can cause severe bleeding. Whether this drug improves survival is not known. Using a novel research approach, this series of studies will evaluate if warfarin improves survival in SSc-PAH. We will use innovative techniques to study if warfarin improves survival by comparing the survival of SSc-PAH patients who did and did not take warfarin. This research will be the first to study if warfarin improves survival in this deadly disease, and will develop innovative research methods for all researchers who study uncommon diseases.
Competitiondate
201009
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Johnson, Sindhu R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $172,500~ $0~
University of Toronto - $172,500 Grant (2010-11) | Canada Spends